B-intervention	0	7	Topical
I-intervention	8	17	silymarin
O	18	32	administration
O	33	36	for
O	37	47	prevention
O	48	50	of
B-condition	51	56	acute
I-condition	57	72	radiodermatitis
O	73	75	in
O	76	82	breast
O	83	89	cancer
O	90	98	patients
O	98	99	:
O	100	101	A
O	102	112	randomized
O	112	113	,
O	114	120	double
O	120	121	-
O	121	126	blind
O	126	127	,
O	128	135	placebo
O	135	136	-
O	136	146	controlled
O	147	155	clinical
O	156	161	trial
O	161	162	.

O	163	172	Radiation
O	172	173	-
O	173	180	induced
O	181	191	dermatitis
O	192	194	is
O	195	198	one
O	199	201	of
O	202	205	the
O	206	210	most
O	211	217	common
O	218	222	side
O	223	230	effects
O	231	233	of
O	234	246	radiotherapy
O	246	247	.

O	248	257	Silymarin
O	257	258	,
O	259	260	a
O	261	270	flavonoid
O	271	280	extracted
O	281	285	from
O	286	289	the
O	290	297	Silybum
O	298	306	marianum
O	306	307	,
O	308	316	exhibits
O	317	328	antioxidant
O	329	332	and
O	333	337	anti
O	337	338	-
O	338	350	inflammatory
O	351	361	activities
O	361	362	.

O	363	366	The
O	367	374	purpose
O	375	377	of
O	378	382	this
O	383	388	study
O	389	392	was
O	393	395	to
O	396	407	investigate
O	408	411	the
O	412	420	efficacy
O	421	423	of
O	424	433	silymarin
O	434	437	gel
O	438	440	in
O	441	451	prevention
O	452	454	of
O	455	470	radiodermatitis
O	471	473	in
O	474	482	patients
O	483	487	with
O	488	494	breast
O	495	501	cancer
O	501	502	.

O	503	509	During
O	510	514	this
O	515	525	randomized
O	525	526	,
O	527	533	double
O	533	534	-
O	534	541	blinded
O	541	542	,
O	543	550	placebo
O	550	551	-
O	551	561	controlled
O	562	570	clinical
O	571	576	trial
O	576	577	,
O	578	581	the
O	582	592	preventive
O	593	599	effect
O	600	602	of
O	603	612	silymarin
O	613	614	1
O	614	615	%
O	616	619	gel
O	620	623	was
O	624	632	assessed
O	633	635	in
O	636	646	comparison
O	647	651	with
B-control	652	659	placebo
O	659	660	,
O	661	663	on
O	664	679	radiodermatitis
O	680	690	occurrence
O	690	691	.

B-total-participants	692	697	Forty
O	698	706	patients
O	707	715	randomly
O	716	724	received
O	725	734	silymarin
O	735	738	gel
O	739	741	or
O	742	749	placebo
O	750	761	formulation
O	762	764	on
O	765	770	chest
O	771	775	wall
O	776	780	skin
O	781	790	following
O	791	799	modified
O	800	807	radical
O	808	818	mastectomy
O	818	819	,
O	820	824	once
O	825	830	daily
O	831	839	starting
O	840	842	at
O	843	846	the
O	847	852	first
O	853	856	day
O	857	859	of
O	860	872	radiotherapy
O	873	876	for
O	877	878	5
O	879	884	weeks
O	884	885	.

O	886	901	Radiodermatitis
O	902	910	severity
O	911	914	was
O	915	923	assessed
O	924	930	weekly
O	931	936	based
O	937	939	on
O	940	949	Radiation
O	950	957	Therapy
O	958	966	Oncology
O	967	972	Group
O	973	974	(
O	974	978	RTOG
O	978	979	)
O	980	983	and
O	984	992	National
O	993	999	Cancer
O	1000	1009	Institute
O	1010	1016	Common
O	1017	1028	Terminology
O	1029	1032	for
O	1033	1040	Adverse
O	1041	1047	Events
O	1048	1049	(
O	1049	1052	NCI
O	1052	1053	-
O	1053	1058	CTCAE
O	1058	1059	)
O	1060	1068	criteria
O	1069	1083	radiodermatits
O	1084	1091	grading
O	1092	1097	scale
O	1098	1101	for
O	1102	1103	5
O	1104	1109	weeks
O	1109	1110	.

O	1111	1114	The
B-outcome	1115	1121	median
I-outcome	1122	1125	NCI
I-outcome	1125	1126	-
I-outcome	1126	1131	CTCAE
I-outcome	1132	1135	and
I-outcome	1136	1140	RTOG
I-outcome	1141	1147	scores
O	1148	1152	were
O	1153	1166	significantly
O	1167	1172	lower
O	1173	1175	in
O	1176	1185	silymarin
O	1186	1191	group
O	1192	1194	at
O	1195	1198	the
O	1199	1202	end
O	1203	1205	of
O	1206	1209	the
O	1210	1215	third
O	1216	1218	to
O	1219	1224	fifth
O	1225	1230	weeks
O	1231	1232	(
O	1232	1233	p
O	1234	1239	value
O	1240	1241	<
O	1242	1243	0
O	1243	1244	.
O	1244	1246	05
O	1246	1247	)
O	1247	1248	.

O	1249	1252	The
B-outcome	1253	1259	scores
I-outcome	1260	1269	increased
I-outcome	1270	1283	significantly
O	1284	1286	in
O	1287	1291	both
O	1292	1299	placebo
O	1300	1303	and
O	1304	1313	silymarin
O	1314	1320	groups
O	1321	1327	during
O	1328	1340	radiotherapy
O	1340	1341	,
O	1342	1345	but
O	1346	1351	there
O	1352	1355	was
O	1356	1357	a
O	1358	1363	delay
O	1364	1366	in
O	1367	1382	radiodermatitis
O	1383	1394	development
O	1395	1398	and
O	1399	1410	progression
O	1411	1413	in
O	1414	1423	silymarin
O	1424	1429	group
O	1429	1430	.

O	1431	1443	Prophylactic
O	1444	1458	administration
O	1459	1461	of
O	1462	1471	silymarin
O	1472	1475	gel
O	1476	1481	could
O	1482	1495	significantly
O	1496	1502	reduce
O	1503	1506	the
O	1507	1515	severity
O	1516	1518	of
O	1519	1534	radiodermatitis
O	1535	1538	and
O	1539	1544	delay
O	1545	1548	its
O	1549	1559	occurrence
O	1560	1565	after
O	1566	1567	5
O	1568	1573	weeks
O	1574	1576	of
O	1577	1588	application
O	1588	1589	.
